# Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection

> **NCT04553068** · PHASE3 · COMPLETED · sponsor: **Evofem Inc.** · enrollment: 1892 (actual)

## Conditions studied

- Sexually Transmitted Diseases
- Gonorrhea
- Chlamydia

## Interventions

- **DRUG:** EVO100
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04553068
- **Lead sponsor:** Evofem Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-15
- **Primary completion:** 2022-07-28
- **Final completion:** 2022-07-28
- **Target enrollment:** 1892 (ACTUAL)
- **Last updated:** 2024-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04553068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04553068, "Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04553068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*